Rylkova Daria, Boissoneault Jeffrey, Isaac Shani, Prado Melissa, Shah Hina P, Bruijnzeel Adrie W
Department of Psychiatry, University of Florida, Gainesville, FL 32610, USA.
Neuropeptides. 2008 Jun;42(3):215-27. doi: 10.1016/j.npep.2008.03.004. Epub 2008 May 12.
Tobacco addiction is a chronic disorder that is characterized by dysphoria upon smoking cessation and relapse after periods of abstinence. Previous research suggests that Neuropeptide Y (NPY) and Y1 receptor agonists attenuate negative affective states and somatic withdrawal signs. The aim of the present experiments was to investigate the effects of NPY and the specific Y1 receptor agonist [D-His(26)]-NPY on the deficit in brain reward function and somatic signs associated with nicotine withdrawal in rats. The intracranial self-stimulation procedure was used to assess the effects of nicotine withdrawal on brain reward function as this procedure can provide a quantitative measure of emotional states in rodents. Elevations in brain reward thresholds are indicative of a deficit in brain reward function. In the first experiment, NPY did not prevent the elevations in brain reward thresholds associated with precipitated nicotine withdrawal and elevated the brain reward thresholds of the saline-treated control rats. Similar to NPY, [D-His(26)]-NPY did not prevent the elevations in brain reward thresholds associated with precipitated nicotine withdrawal and elevated the brain reward thresholds of the saline-treated control rats. Neither NPY nor [D-His(26)]-NPY affected the response latencies. In a separate experiment, it was demonstrated that the specific Y1 receptor antagonist BIBP-3226 prevented the NPY-induced elevations in brain reward thresholds. NPY attenuated the overall somatic signs associated with precipitated nicotine withdrawal. [D-His(26)]-NPY did not affect the overall somatic signs associated with precipitated nicotine withdrawal, but decreased the number of abdominal constrictions. Both NPY and [D-His(26)]-NPY attenuated the overall somatic signs associated with spontaneous nicotine withdrawal. These findings indicate that NPY and [D-His(26)]-NPY attenuate somatic nicotine withdrawal signs, but do not prevent the deficit in brain reward function associated with precipitated nicotine withdrawal. In addition, NPY decreases the sensitivity to rewarding electrical stimuli via an Y1 dependent mechanism.
烟草成瘾是一种慢性疾病,其特征是戒烟时出现烦躁不安以及在禁欲一段时间后复发。先前的研究表明,神经肽Y(NPY)和Y1受体激动剂可减轻负面情绪状态和躯体戒断症状。本实验的目的是研究NPY和特异性Y1受体激动剂[D-组氨酸(26)]-NPY对大鼠脑奖赏功能缺陷以及与尼古丁戒断相关的躯体症状的影响。采用颅内自我刺激程序来评估尼古丁戒断对脑奖赏功能的影响,因为该程序可以对啮齿动物的情绪状态进行定量测量。脑奖赏阈值升高表明脑奖赏功能存在缺陷。在第一个实验中,NPY未能阻止与急性尼古丁戒断相关的脑奖赏阈值升高,反而提高了生理盐水处理的对照大鼠的脑奖赏阈值。与NPY相似,[D-组氨酸(26)]-NPY也未能阻止与急性尼古丁戒断相关的脑奖赏阈值升高,且提高了生理盐水处理的对照大鼠的脑奖赏阈值。NPY和[D-组氨酸(26)]-NPY均未影响反应潜伏期。在另一个实验中,证明了特异性Y-1受体拮抗剂BIBP-3226可阻止NPY诱导的脑奖赏阈值升高。NPY减轻了与急性尼古丁戒断相关的总体躯体症状。[D-组氨酸(26)]-NPY未影响与急性尼古丁戒断相关的总体躯体症状,但减少了腹部收缩次数。NPY和[D-组氨酸(26)]-NPY均减轻了与自发尼古丁戒断相关的总体躯体症状。这些发现表明,NPY和[D-组氨酸(26)]-NPY可减轻躯体尼古丁戒断症状,但不能预防与急性尼古丁戒断相关的脑奖赏功能缺陷。此外,NPY通过Y1依赖性机制降低对奖赏性电刺激的敏感性。